OncoMatch/Clinical Trials/NCT06996782
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Is NCT06996782 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for advanced or metastatic non-small cell lung cancer.
Treatment: Rilvegostomig · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel · Ramucirumab — The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumour proportion score (TPS) ≥ 1% (TPS ≥ 1%)
Programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥ 1% (per local report) [Sub Study 2]
Excluded: EGFR mutation
Participants with epidermal growth factor receptor mutations ... for which targeted therapy is approved in the first line per local standard of care [excluded].
Excluded: ALK fusion
Participants with ... anaplastic lymphoma receptor fusions ... for which targeted therapy is approved in the first line per local standard of care [excluded].
Disease stage
Required: Stage IV
Metastatic disease required
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy received for advanced or mNSCLC [Sub Study 2]
Cannot have received: anti-TIGIT therapy
Prior exposure to an anti-T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif domains (TIGIT) therapy or immune-oncology agent such as anti-programmed cell death protein 1 (PD-1), anti-PD-L1, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), or any other anti-cancer therapy targeting immune-regulatory receptors or mechanisms [Sub Study 2]
Cannot have received: anti-PD-1 therapy
Prior exposure to ... anti-programmed cell death protein 1 (PD-1) ... [Sub Study 2]
Cannot have received: anti-PD-L1 therapy
Prior exposure to ... anti-PD-L1 ... [Sub Study 2]
Cannot have received: anti-CTLA-4 therapy
Prior exposure to ... anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) ... [Sub Study 2]
Cannot have received: anti-VEGF therapy
Prior exposure to anti-vascular endothelial growth factor (VEGF) therapy [Sub Study 2]
Cannot have received: platinum-based chemotherapy (cisplatin, carboplatin)
Exception: medical contraindication to protocol-specified platinum doublet regimens or ramucirumab
Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab [Sub Study 2]
Cannot have received: antibody-drug conjugate (ramucirumab)
Exception: medical contraindication
Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab [Sub Study 2]
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Phoenix, Arizona
- Research Site · Santa Rosa, California
- Research Site · Jacksonville, Florida
- Research Site · Baltimore, Maryland
- Research Site · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06996782 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 tumour proportion score (TPS) ≥ 1% is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify